Cap under $10m, Gross Profit almost doubled (9 months) 44,782,498 vs 24,205,310, 3 months up almost 50%.solid balance sheet too:
Total current assets(45,767,950) /Total current liabilities(28,469,386) ratio= ~1.7 (Solid) Total assets(142,448,965)/Total liabilities(including long term debt,147,547,884) ratio = ~1
"The company has a consensus rating of Buy and a consensus price target of $4.45".
Beside a Record revenue the Company recently did some more major steps forward :
1. Uplisted to NYSE MKT (October 19, 2015)
2. its wholly owned subsidiary, Bacterin International, Inc., has received notification that the United States Patent and Trademark Office has issued US Patent No. 9,114,191 entitled "Process for Demineralization of Bone Matrix with Preservation of Natural Growth Factors." (Sep 22, 2015)
3. “Xtant Medical Received FDA Clearance for the Xsert™ Lumbar Expandable Interbody System,” (Nov 23, 2016). Xtant Medical estimates the U.S market for lumbar interbody devices at $1.3M and growing. The worldwide market for Demineralized Bone Matrix (DBM) is estimated at $485M. Xsert will be available in an initial product release in mid 2017. btw. also Received FDA Clearance +CE Mark of the Aranax(TM) Cervical Plate.
4. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of Buy and a consensus price target of $4.45. including a new Covered by Analysts at Maxim Group (on last friday).
My posts are my opinion and should not be used as investment advice. Make your own decisions in your stock trades.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.